The biologics landscape is evolving rapidly. From monoclonal antibodies to antibody-drug conjugates (ADCs), bispecifics, and nanobodies, today’s therapeutic pipelines demand higher throughput, better data quality, and faster iteration cycles.
At the center of this shift is a convergence of AI-driven protein design and label-free analytical technologies, enabling researchers to overcome longstanding bottlenecks in binding analysis, assay development, and early-stage screening.
A new generation of computationally engineered binding proteins is redefining how laboratories approach biolayer interferometry (BLI) and antibody characterization.
How traditional binding assays are reaching their limits
Biolayer interferometry (BLI) has long been a workhorse for real-time, label-free kinetic analysis. Its advantages are well established:
However, conventional antibody-based BLI capture probes introduce several persistent challenges, including:
These limitations become especially problematic when working with picomolar affinity interactions or complex biological matrices.
Recent advances in computational protein design
AI-based modeling approaches have now enabled the creation of engineered binding scaffolds optimized for stability, specificity, and optical performance.
Expanded BLI Applications using computationally designed probes include:
The bigger picture: AI-driven protein engineering
The emergence of AI-designed binding proteins signals a broader shift in life sciences:
Download the Full Whitepaper and uncover detailed performance data, workflow diagrams, and application case studies demonstrating how AI-designed probes are transforming BLI assays, antibody discovery, and the biologics development pipeline.